breast neoplasms

Summary

Summary: Tumors or cancer of the human BREAST.

Top Publications

  1. ncbi A gene-expression signature as a predictor of survival in breast cancer
    Marc J van de Vijver
    Division of Diagnostic Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands
    N Engl J Med 347:1999-2009. 2002
  2. ncbi Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study
    Lisa A Carey
    Division of Hematology Oncology, School of Public Health, Department of Epidemiology, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC 27599 7305, USA
    JAMA 295:2492-502. 2006
  3. pmc A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes
    Richard M Neve
    Life Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, California 94270, USA
    Cancer Cell 10:515-27. 2006
  4. pmc A pathway-based classification of human breast cancer
    Michael L Gatza
    Duke Institute for Genome Sciences and Policy, Duke University Medical Center, Durham, NC 27710, USA
    Proc Natl Acad Sci U S A 107:6994-9. 2010
  5. pmc Prospective identification of tumorigenic breast cancer cells
    Muhammad Al-Hajj
    Department of Internal Medicine, Comprehensive Cancer Center, University of Michigan Medical School, Ann Arbor, MI 48109, USA
    Proc Natl Acad Sci U S A 100:3983-8. 2003
  6. ncbi MicroRNA gene expression deregulation in human breast cancer
    Marilena V Iorio
    Comprehensive Cancer Center, Ohio State University, Columbus, Ohio 43210, USA
    Cancer Res 65:7065-70. 2005
  7. pmc The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups
    Christina Curtis
    Department of Oncology, University of Cambridge, Hills Road, Cambridge CB2 2XZ, UK
    Nature 486:346-52. 2012
  8. ncbi The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1
    Philip A Gregory
    Hanson Institute and Division of Human Immunology, Institute of Medical and Veterinary Science, Adelaide, SA 5000, Australia
    Nat Cell Biol 10:593-601. 2008
  9. ncbi Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene
    D J Slamon
    Science 235:177-82. 1987
  10. ncbi American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer
    Antonio C Wolff
    American Society of Clinical Oncology, Alexandria, VA, USA
    J Clin Oncol 25:118-45. 2007

Detail Information

Publications248 found, 100 shown here

  1. ncbi A gene-expression signature as a predictor of survival in breast cancer
    Marc J van de Vijver
    Division of Diagnostic Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands
    N Engl J Med 347:1999-2009. 2002
    ..A more accurate means of prognostication in breast cancer will improve the selection of patients for adjuvant systemic therapy...
  2. ncbi Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study
    Lisa A Carey
    Division of Hematology Oncology, School of Public Health, Department of Epidemiology, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC 27599 7305, USA
    JAMA 295:2492-502. 2006
    ..Gene expression analysis has identified several breast cancer subtypes, including basal-like, human epidermal growth factor receptor-2 positive/estrogen receptor negative (HER2+/ER-), luminal A, and luminal B...
  3. pmc A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes
    Richard M Neve
    Life Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, California 94270, USA
    Cancer Cell 10:515-27. 2006
    ..We show, using Trastuzumab (Herceptin) monotherapy as an example, that the system can be used to identify molecular features that predict or indicate response to targeted therapies or other physiological perturbations...
  4. pmc A pathway-based classification of human breast cancer
    Michael L Gatza
    Duke Institute for Genome Sciences and Policy, Duke University Medical Center, Durham, NC 27710, USA
    Proc Natl Acad Sci U S A 107:6994-9. 2010
    ..We propose that this classification scheme provides a basis for understanding the complex mechanisms of oncogenesis that give rise to these tumors and to identify rational opportunities for combination therapies...
  5. pmc Prospective identification of tumorigenic breast cancer cells
    Muhammad Al-Hajj
    Department of Internal Medicine, Comprehensive Cancer Center, University of Michigan Medical School, Ann Arbor, MI 48109, USA
    Proc Natl Acad Sci U S A 100:3983-8. 2003
    ..Furthermore, because these cells drive tumor development, strategies designed to target this population may lead to more effective therapies...
  6. ncbi MicroRNA gene expression deregulation in human breast cancer
    Marilena V Iorio
    Comprehensive Cancer Center, Ohio State University, Columbus, Ohio 43210, USA
    Cancer Res 65:7065-70. 2005
    ..We could identify miRNAs whose expression was correlated with specific breast cancer biopathologic features, such as estrogen and progesterone receptor expression, tumor stage, vascular invasion, or proliferation index...
  7. pmc The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups
    Christina Curtis
    Department of Oncology, University of Cambridge, Hills Road, Cambridge CB2 2XZ, UK
    Nature 486:346-52. 2012
    ..Our results provide a novel molecular stratification of the breast cancer population, derived from the impact of somatic CNAs on the transcriptome...
  8. ncbi The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1
    Philip A Gregory
    Hanson Institute and Division of Human Immunology, Institute of Medical and Veterinary Science, Adelaide, SA 5000, Australia
    Nat Cell Biol 10:593-601. 2008
    ..Expression of the miR-200 family was also lost in regions of metaplastic breast cancer specimens lacking E-cadherin. These data suggest that downregulation of the microRNAs may be an important step in tumour progression...
  9. ncbi Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene
    D J Slamon
    Science 235:177-82. 1987
    ..These data indicate that this gene may play a role in the biologic behavior and/or pathogenesis of human breast cancer...
  10. ncbi American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer
    Antonio C Wolff
    American Society of Clinical Oncology, Alexandria, VA, USA
    J Clin Oncol 25:118-45. 2007
    ..To develop a guideline to improve the accuracy of human epidermal growth factor receptor 2 (HER2) testing in invasive breast cancer and its utility as a predictive marker...
  11. pmc An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors
    Ittai Ben-Porath
    Whitehead Institute for Biomedical Research, Cambridge, Massachusetts 02142, USA
    Nat Genet 40:499-507. 2008
    ....
  12. pmc ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome
    Christophe Ginestier
    Department of Internal Medicine, Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI 48109, USA
    Cell Stem Cell 1:555-67. 2007
    ..These findings offer an important new tool for the study of normal and malignant breast stem cells and facilitate the clinical application of stem cell concepts...
  13. ncbi Tumour invasion and metastasis initiated by microRNA-10b in breast cancer
    Li Ma
    Whitehead Institute for Biomedical Research and Department of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts 02142, USA
    Nature 449:682-8. 2007
    ....
  14. ncbi Involvement of chemokine receptors in breast cancer metastasis
    A Muller
    Department of Immunology, DNAX Research Institute, Palo Alto, California 94304, USA
    Nature 410:50-6. 2001
    ..Our findings indicate that chemokines and their receptors have a critical role in determining the metastatic destination of tumour cells...
  15. ncbi let-7 regulates self renewal and tumorigenicity of breast cancer cells
    Fengyan Yu
    Department of Breast Surgery, No 2 Affiliated Hospital, Sun Yat Sen University, Guangzhou 510120, People s Republic of China
    Cell 131:1109-23. 2007
    ..Therefore let-7 regulates multiple BT-IC stem cell-like properties by silencing more than one target...
  16. pmc Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011
    A Goldhirsch
    International Breast Cancer Study Group, Department of Medicine, European Institute of Oncology, Milan, Italy
    Ann Oncol 22:1736-47. 2011
    ..Broad treatment recommendations are presented, recognizing that detailed treatment decisions need to consider disease extent, host factors, patient preferences, and social and economic constraints...
  17. ncbi Environmental and heritable factors in the causation of cancer--analyses of cohorts of twins from Sweden, Denmark, and Finland
    P Lichtenstein
    Department of Medical Epidemiology, Karolinska Institute, Stockholm, Sweden
    N Engl J Med 343:78-85. 2000
    ..The contribution of hereditary factors to the causation of sporadic cancer is unclear. Studies of twins make it possible to estimate the overall contribution of inherited genes to the development of malignant diseases...
  18. ncbi Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis
    Jing Yang
    Whitehead Institute for Biomedical Research, 9 Cambridge Center, Cambridge, Massachusetts 02142, USA
    Cell 117:927-39. 2004
    ..These results establish a mechanistic link between Twist, EMT, and tumor metastasis...
  19. ncbi Gene expression profiling predicts clinical outcome of breast cancer
    Laura J van 't Veer
    Division of Diagnostic Oncology, The Netherlands Cancer Institute, 121 Plesmanlaan, 1066 CX Amsterdam, The Netherlands
    Nature 415:530-6. 2002
    ..This gene expression profile will outperform all currently used clinical parameters in predicting disease outcome. Our findings provide a strategy to select patients who would benefit from adjuvant therapy...
  20. ncbi PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer
    J Li
    Department of Pathology, College of Physicians and Surgeons, Columbia University, 630 West 168 Street, New York, NY 10032, USA
    Science 275:1943-7. 1997
    ..These homologies suggest that PTEN may suppress tumor cell growth by antagonizing protein tyrosine kinases and may regulate tumor cell invasion and metastasis through interactions at focal adhesions...
  21. pmc Genes that mediate breast cancer metastasis to lung
    Andy J Minn
    Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Nature 436:518-24. 2005
    ..Others contribute to aggressive growth selectively in the lung. Many encode extracellular proteins and are of previously unknown relevance to cancer metastasis...
  22. doi Diverse somatic mutation patterns and pathway alterations in human cancers
    Zhengyan Kan
    Department of Molecular Biology, Genentech Inc, 1 DNA Way, South San Francisco, California 94080, USA
    Nature 466:869-73. 2010
    ..Our study provides an overview of the mutational spectra across major human cancers and identifies several potential therapeutic targets...
  23. pmc Endogenous human microRNAs that suppress breast cancer metastasis
    Sohail F Tavazoie
    Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Nature 451:147-52. 2008
    ..miR-335 and miR-126 are thus identified as metastasis suppressor microRNAs in human breast cancer...
  24. pmc Association of reactive oxygen species levels and radioresistance in cancer stem cells
    Maximilian Diehn
    Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California 94305, USA
    Nature 458:780-3. 2009
    ....
  25. pmc Supervised risk predictor of breast cancer based on intrinsic subtypes
    Joel S Parker
    Lineberger Comprehensive Cancer Center, Carolina Center for Genome Sciences, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
    J Clin Oncol 27:1160-7. 2009
    ..Test sets from 761 patients (no systemic therapy) were evaluated for prognosis, and 133 patients were evaluated for prediction of pathologic complete response (pCR) to a taxane and anthracycline regimen...
  26. ncbi High frequency of mutations of the PIK3CA gene in human cancers
    Yardena Samuels
    Sidney Kimmel Comprehensive Cancer Center, Howard Hughes Medical Institute, The Johns Hopkins University Medical Institutions, Baltimore, MD 21231, USA
    Science 304:554. 2004
  27. ncbi Triple-negative breast cancer
    William D Foulkes
    Departmentof Oncology and Human Genetics, Research Institute of the McGill University Health Centre, and the Lady Davis Institute of the Jewish General Hospital, McGill University, Montreal, QC H2W 1S6, Canada
    N Engl J Med 363:1938-48. 2010
    ..This review focuses on its origin, molecular and clinical characteristics, and treatment...
  28. pmc Genome remodelling in a basal-like breast cancer metastasis and xenograft
    Li Ding
    The Genome Center at Washington University, St Louis, Missouri 63108, USA
    Nature 464:999-1005. 2010
    ..The differential mutation frequencies and structural variation patterns in metastasis and xenograft compared with the primary tumour indicate that secondary tumours may arise from a minority of cells within the primary tumour...
  29. ncbi Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
    D J Slamon
    Division of Hematology and Oncology, UCLA School of Medicine, Los Angeles, Calif 90095 1678, USA
    N Engl J Med 344:783-92. 2001
    ..The HER2 gene, which encodes the growth factor receptor HER2, is amplified and HER2 is overexpressed in 25 to 30 percent of breast cancers, increasing the aggressiveness of the tumor...
  30. ncbi The Ki-67 protein: from the known and the unknown
    T Scholzen
    Division of Molecular Immunology, Research Center Borstel, Germany
    J Cell Physiol 182:311-22. 2000
    ..There are indications, however, that Ki-67 protein expression is an absolute requirement for progression through the cell-division cycle...
  31. pmc Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
    T Sørlie
    Department of Genetics, The Norwegian Radium Hospital, Montebello, N 0310 Oslo, Norway
    Proc Natl Acad Sci U S A 98:10869-74. 2001
    ....
  32. pmc Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer
    Maggie C U Cheang
    Genetic Pathology Evaluation Centre, Vancouver Coastal Health Research Institute, British Columbia Cancer Agency, and University of British Columbia, Vancouver, BC, Canada
    J Natl Cancer Inst 101:736-50. 2009
    ....
  33. ncbi Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial
    Jacques E Rossouw
    Division of Women s Health Initiative, National Heart, Lung, and Blood Institute, 6705 Rockledge Dr, One Rockledge Ctr, Suite 300, Bethesda, MD 20817
    JAMA 288:321-33. 2002
    ..Despite decades of accumulated observational evidence, the balance of risks and benefits for hormone use in healthy postmenopausal women remains uncertain...
  34. ncbi The consensus coding sequences of human breast and colorectal cancers
    Tobias Sjoblom
    Ludwig Center and Howard Hughes Medical Institute, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA
    Science 314:268-74. 2006
    ..These data define the genetic landscape of two human cancer types, provide new targets for diagnostic and therapeutic intervention, and open fertile avenues for basic research in tumor biology...
  35. pmc Genes that mediate breast cancer metastasis to the brain
    Paula D Bos
    Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Nature 459:1005-9. 2009
    ..This co-option of a brain sialyltransferase highlights the role of cell-surface glycosylation in organ-specific metastatic interactions...
  36. doi Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis
    Mohammad H Forouzanfar
    Institute for Health Metrics and Evaluation, University of Washington, Seattle, USA
    Lancet 378:1461-84. 2011
    ..Breast and cervical cancer are important causes of mortality in women aged ≥15 years. We undertook annual age-specific assessments of breast and cervical cancer in 187 countries...
  37. pmc Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes
    Joseph H Taube
    Department of Molecular Pathology, University of Texas M D Anderson Cancer Center, Houston, TX 77054, USA
    Proc Natl Acad Sci U S A 107:15449-54. 2010
    ..Additionally, the expression level of FOXC1, another EMT inducer, correlates strongly with poor survival of breast cancer patients...
  38. ncbi Mesenchymal stem cells within tumour stroma promote breast cancer metastasis
    Antoine E Karnoub
    Whitehead Institute for Biomedical Research and Massachusetts Institute of Technology, Cambridge, Massachusetts 02142, USA
    Nature 449:557-63. 2007
    ..Collectively, these data demonstrate that the tumour microenvironment facilitates metastatic spread by eliciting reversible changes in the phenotype of cancer cells...
  39. pmc Genome-wide association study identifies five new breast cancer susceptibility loci
    Clare Turnbull
    Section of Cancer Genetics, The Institute of Cancer Research, Sutton, Surrey, UK
    Nat Genet 42:504-7. 2010
    ....
  40. ncbi Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution
    Sohrab P Shah
    Molecular Oncology, BC Cancer Agency, 675 West 10th Avenue, Vancouver V5Z 1L3, Canada
    Nature 461:809-13. 2009
    ..Taken together, our data show that single nucleotide mutational heterogeneity can be a property of low or intermediate grade primary breast cancers and that significant evolution can occur with disease progression...
  41. ncbi Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series
    Christine Desmedt
    Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium
    Clin Cancer Res 13:3207-14. 2007
    ..The aims of this study conducted by TRANSBIG were to independently validate these results and to compare the outcome with clinical risk assessment...
  42. pmc Generation of breast cancer stem cells through epithelial-mesenchymal transition
    Anne Pierre Morel
    Centre Leon Berard, Lyon, France
    PLoS ONE 3:e2888. 2008
    ..The acquisition of these stem and tumorigenic characters is driven by EMT induction...
  43. doi Stromal gene expression predicts clinical outcome in breast cancer
    Greg Finak
    McGill Centre for Bioinformatics, 3775 University Street, McGill University, Quebec H3A 2B4, Canada
    Nat Med 14:518-27. 2008
    ..Genes represented in the SDPP reveal the strong prognostic capacity of differential immune responses as well as angiogenic and hypoxic responses, highlighting the importance of stromal biology in tumor progression...
  44. ncbi The genomic landscapes of human breast and colorectal cancers
    Laura D Wood
    Ludwig Center for Cancer Genetics and Therapeutics and Howard Hughes Medical Institute at Johns Hopkins Kimmel Cancer Center, Baltimore, MD 21231, USA
    Science 318:1108-13. 2007
    ..These results have implications for understanding the nature and heterogeneity of human cancers and for using personal genomics for tumor diagnosis and therapy...
  45. pmc Complex landscapes of somatic rearrangement in human breast cancer genomes
    Philip J Stephens
    Wellcome Trust Sanger Institute, Hinxton, Cambridge CB10 1SA, UK
    Nature 462:1005-10. 2009
    ..The study provides a new perspective on cancer genomes, highlighting the diversity of somatic rearrangements and their potential contribution to cancer development...
  46. ncbi Circulating tumor cells, disease progression, and survival in metastatic breast cancer
    Massimo Cristofanilli
    Department of Breast Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    N Engl J Med 351:781-91. 2004
    ..We tested the hypothesis that the level of circulating tumor cells can predict survival in metastatic breast cancer...
  47. ncbi Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis
    Christos Sotiriou
    Functional Genomics and Translational Research Unit, Universite Libre de Bruxelles, Brussels, Belgium
    J Natl Cancer Inst 98:262-72. 2006
    ..We examined whether histologic grade was associated with gene expression profiles of breast cancers and whether such profiles could be used to improve histologic grading...
  48. ncbi Multidrug resistance in cancer: role of ATP-dependent transporters
    Michael M Gottesman
    Laboratory of Cell Biology and Cancer Therapeutics Branch, The Center for Cancer Research, National Institutes of Health, Bethesda, Maryland 20892, USA
    Nat Rev Cancer 2:48-58. 2002
    ..Therefore, the ability to predict and circumvent drug resistance is likely to improve chemotherapy...
  49. ncbi A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer
    Soonmyung Paik
    Division of Pathology, Operation Center, and the Biostatistics Center, National Surgical Adjuvant Breast and Bowel Project, Pittsburgh 15212, USA
    N Engl J Med 351:2817-26. 2004
    ..The likelihood of distant recurrence in patients with breast cancer who have no involved lymph nodes and estrogen-receptor-positive tumors is poorly defined by clinical and histopathological measures...
  50. pmc Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer
    Aleix Prat
    Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, 27599, USA
    Breast Cancer Res 12:R68. 2010
    ..Here, we comprehensively characterize the recently identified claudin-low tumor subtype...
  51. doi Breast cancer statistics, 2011
    Carol DeSantis
    Epidemiologist, Surveillance Research, American Cancer Society, Atlanta, GA 30303, USA
    CA Cancer J Clin 61:409-18. 2011
    ..Continued progress in the control of breast cancer will require sustained and increased efforts to provide high-quality screening, diagnosis, and treatment to all segments of the population...
  52. doi Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers
    Elgene Lim
    The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia
    Nat Med 15:907-13. 2009
    ..Our findings suggest that an aberrant luminal progenitor population is a target for transformation in BRCA1-associated basal tumors ...
  53. ncbi Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer
    Bernard Fisher
    National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA 15212 5234, USA
    N Engl J Med 347:1233-41. 2002
    ..In 1976, we initiated a randomized trial to determine whether lumpectomy with or without radiation therapy was as effective as total mastectomy for the treatment of invasive breast cancer...
  54. pmc Epithelial-mesenchymal transition in cancer: parallels between normal development and tumor progression
    Douglas S Micalizzi
    Department of Obstetrics and Gynecology, University of Colorado School of Medicine, Aurora, CO 80045, USA
    J Mammary Gland Biol Neoplasia 15:117-34. 2010
    ..This review focuses on the parallels between epithelial plasticity/EMT in the mammary gland and other organs during development, and on a selection of developmental EMT regulators that are misexpressed specifically during breast cancer...
  55. ncbi Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer
    Yixin Wang
    Veridex LLC, a Johnson and Johnson Company, San Diego, CA, USA
    Lancet 365:671-9. 2005
    ....
  56. pmc Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009
    A Goldhirsch
    International Breast Cancer Study Group, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
    Ann Oncol 20:1319-29. 2009
    ..The threshold for indication of each systemic treatment modality thus depends on different criteria which have been separately listed to clarify the therapeutic decision-making algorithm...
  57. pmc Adjuvant trastuzumab in HER2-positive breast cancer
    Dennis Slamon
    Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, CA 90095 1678, USA
    N Engl J Med 365:1273-83. 2011
    ..We wanted to evaluate the efficacy and safety of a new nonanthracycline regimen with trastuzumab...
  58. pmc A pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis
    Scott Valastyan
    Whitehead Institute for Biomedical Research, Cambridge, MA 02142, USA
    Cell 137:1032-46. 2009
    ..Indeed, RhoA re-expression partially reverses miR-31-imposed metastasis suppression. These findings indicate that miR-31 uses multiple mechanisms to oppose metastasis...
  59. pmc Repeated observation of breast tumor subtypes in independent gene expression data sets
    Therese Sorlie
    Department of Genetics, Stanford University School of Medicine, Stanford, CA 94305, USA
    Proc Natl Acad Sci U S A 100:8418-23. 2003
    ..Our results strongly support the idea that many of these breast tumor subtypes represent biologically distinct disease entities...
  60. ncbi Triple-negative breast cancer: clinical features and patterns of recurrence
    Rebecca Dent
    Department of Medical Oncology, Sunnybrook Health Sciences Center, University of Toronto, Ontario, Canada
    Clin Cancer Res 13:4429-34. 2007
    ..To compare the clinical features, natural history, and outcomes for women with "triple-negative" breast cancer with women with other types of breast cancer...
  61. pmc Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells
    Yohei Shimono
    Stanford Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, 1050 Arastradero Road, Palo Alto, CA 94304, USA
    Cell 138:592-603. 2009
    ..The coordinated downregulation of three microRNA clusters and the similar functional regulation of clonal expansion by miR-200c provide a molecular link that connects BCSCs with normal stem cells...
  62. ncbi American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer
    Lyndsay Harris
    Yale Cancer Center, Yale University, New Haven, CT, USA
    J Clin Oncol 25:5287-312. 2007
    ..To update the recommendations for the use of tumor marker tests in the prevention, screening, treatment, and surveillance of breast cancer...
  63. pmc Matrix crosslinking forces tumor progression by enhancing integrin signaling
    Kandice R Levental
    Department of Bioengineering and Institute for Medicine and Engineering, University of Pennsylvania, Philadelphia, PA 19104, USA
    Cell 139:891-906. 2009
    ..These data show how collagen crosslinking can modulate tissue fibrosis and stiffness to force focal adhesions, growth factor signaling and breast malignancy...
  64. ncbi Programmed cell death 4 (PDCD4) is an important functional target of the microRNA miR-21 in breast cancer cells
    Lisa B Frankel
    Biotech Research and Innovation Centre, Bioinformatics Centre, University of Copenhagen, DK 2200 N Copenhagen, Denmark
    J Biol Chem 283:1026-33. 2008
    ..We furthermore found that the tumor suppressor protein Programmed Cell Death 4 (PDCD4) is regulated by miR-21 and demonstrated that PDCD4 is a functionally important target for miR-21 in breast cancer cells...
  65. pmc MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1
    Tyler E Miller
    Department of Molecular and Cellular Biochemistry, College of Medicine, Ohio State University, Columbus, Ohio 43210, USA
    J Biol Chem 283:29897-903. 2008
    ..This finding also provides the rationale for the application of altered expression of specific miRNAs as a predictive tamoxifen-resistant breast cancer marker...
  66. pmc microRNAs exhibit high frequency genomic alterations in human cancer
    Lin Zhang
    Center for Research on Reproduction and Women s Health, University of Pennsylvania, Philadelphia, PA 19104, USA
    Proc Natl Acad Sci U S A 103:9136-41. 2006
    ..These findings support the notion that copy number alterations of miRNAs and their regulatory genes are highly prevalent in cancer and may account partly for the frequent miRNA gene deregulation reported in several tumor types...
  67. ncbi miR-21-mediated tumor growth
    M L Si
    Department of Medical Microbiology, Immunology and Cell Biology, Southern Illinois University School of Medicine, Springfield, IL 62794, USA
    Oncogene 26:2799-803. 2007
    ..Together, these results suggest that miR-21 functions as an oncogene and modulates tumorigenesis through regulation of genes such as bcl-2 and thus, it may serve as a novel therapeutic target...
  68. ncbi Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy
    Xiaoxian Li
    Breast Center at Baylor College of Medicine, 1 Baylor Plaza BCM 600, TX 77030, USA
    J Natl Cancer Inst 100:672-9. 2008
    ....
  69. pmc Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995-2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data
    M P Coleman
    Cancer Research UK Cancer Survival Group, London School of Hygiene and Tropical Medicine, London, UK
    Lancet 377:127-38. 2011
    ..This is the first study in a programme to investigate international survival disparities, with the aim of informing health policy to raise standards and reduce inequalities in survival...
  70. pmc Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature
    Emmanuelle Charafe-Jauffret
    Centre de Recherche en Cancerologie de Marseille, Laboratoire d Oncologie Moleculaire, UMR891 Inserm Institut Paoli Calmettes, Universite de la Mediterranee, Marseille, France
    Cancer Res 69:1302-13. 2009
    ....
  71. ncbi A multigenic program mediating breast cancer metastasis to bone
    Yibin Kang
    Cell Biology Program and Howard Hughes Medical Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Cancer Cell 3:537-49. 2003
    ....
  72. pmc Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures
    Pratyaksha Wirapati
    Swiss Institute of Bioinformatics, Batiment Genopode, University of Lausanne, 1015 Lausanne, Switzerland
    Breast Cancer Res 10:R65. 2008
    ....
  73. ncbi American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer
    Antonio C Wolff
    American Society of Clinical Oncology, Alexandria, VA and the College of American Pathologists, Northfield, IL, USA
    Arch Pathol Lab Med 131:18-43. 2007
    ..To develop a guideline to improve the accuracy of human epidermal growth factor receptor 2(HER2) testing in invasive breast cancer and its utility as a predictive marker...
  74. ncbi Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer
    Charles L Vogel
    University of Miami School of Medicine, Comprehensive Cancer Research Group Inc, and Columbia Cancer Research Network of Florida, Miami, FL, USA
    J Clin Oncol 20:719-26. 2002
    ..To evaluate the efficacy and safety of first-line, single-agent trastuzumab in women with HER2-overexpressing metastatic breast cancer...
  75. doi Metastatic behavior of breast cancer subtypes
    Hagen Kennecke
    Vancouver Clinic, Division of Medical Oncology, British Columbia Cancer Agency, Vancouver, British Columbia, Canada
    J Clin Oncol 28:3271-7. 2010
    ..Prognostic and predictive factors are well established in early-stage breast cancer, but less is known about which metastatic sites will be affected...
  76. pmc Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors
    Jason I Herschkowitz
    Lineberger Comprehensive Cancer Center
    Genome Biol 8:R76. 2007
    ..To address this need, we characterized mammary tumor gene expression profiles from 13 different murine models using DNA microarrays and compared the resulting data to those from human breast tumors...
  77. ncbi Induction of autophagy and inhibition of tumorigenesis by beclin 1
    X H Liang
    Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York 10032, USA
    Nature 402:672-6. 1999
    ..These findings suggest that decreased expression of autophagy proteins may contribute to the development or progression of breast and other human malignancies...
  78. ncbi The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation
    Tiffany M Phillips
    Department of Radiation Oncology, David Geffen School of Medicine at UCLA, 10833 Le Conte Ave, Los Angeles, CA 90095 1714, USA
    J Natl Cancer Inst 98:1777-85. 2006
    ..Cancer-initiating cells can now be prospectively isolated from breast cancer cell lines and tumor samples and propagated as mammospheres in vitro under serum-free conditions...
  79. ncbi Trastuzumab--mechanism of action and use in clinical practice
    Clifford A Hudis
    Breast Cancer Medicine Service, Solid Tumor Division, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA
    N Engl J Med 357:39-51. 2007
  80. pmc A systems biology approach for pathway level analysis
    Sorin Draghici
    Karmanos Cancer Institute, Wayne State University, Detroit, Michigan 48202, USA
    Genome Res 17:1537-45. 2007
    ..This analysis method has been implemented as a Web-based tool, Pathway-Express, freely available as part of the Onto-Tools (http://vortex.cs.wayne.edu)...
  81. ncbi Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer
    Kenneth R Hess
    Department of Biostatistics and Applied Mathematics, The University of Texas M D Anderson Cancer Center, Houston, TX 77230 1439, USA
    J Clin Oncol 24:4236-44. 2006
    ..We developed a multigene predictor of pathologic complete response (pCR) to preoperative weekly paclitaxel and fluorouracil-doxorubicin-cyclophosphamide (T/FAC) chemotherapy and assessed its predictive accuracy on independent cases...
  82. pmc Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features
    Chad J Creighton
    Department of Molecular and Cellular Biology, Division of Biostatistics, Dan L Duncan Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA
    Proc Natl Acad Sci U S A 106:13820-5. 2009
    ..Targeting proteins involved in EMT may provide a therapeutic strategy for eliminating surviving cells to prevent recurrence and improve long-term survival in breast cancer patients...
  83. doi Systemic spread is an early step in breast cancer
    Yves Hüsemann
    Department of Pathology, Division of Oncogenomics, University of Regensburg, Regensburg 93053, Germany
    Cancer Cell 13:58-68. 2008
    ..Therefore, release from dormancy of early-disseminated cancer cells may frequently account for metachronous metastasis...
  84. ncbi Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures
    Jayanta Debnath
    Department of Cell Biology, Harvard Medical School, 240 Longwood Avenue, Boston, MA 02115, USA
    Methods 30:256-68. 2003
    ....
  85. ncbi Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade
    Sherene Loi
    Jules Bordet Institute Machine Learning Group, Universite Libre de Bruxelles, Brussels, Belgium
    J Clin Oncol 25:1239-46. 2007
    ..However, although the basal and the ErbB2 subtypes are repeatedly recognized, identification of estrogen receptor (ER) -positive subtypes has been inconsistent. Therefore, refinement of their molecular definition is needed...
  86. ncbi Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype
    Maggie C U Cheang
    Genetic Pathology Evaluation Centre, Vancouver Coastal Health Research Institute, British Columbia Cancer Agency, and University of British Columbia, Vancouver, British Columbia, Canada
    Clin Cancer Res 14:1368-76. 2008
    ..This study directly compares the prognostic significance between three- and five-biomarker surrogate panels to define intrinsic breast cancer subtypes, using a large clinically annotated series of breast tumors...
  87. pmc American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer
    M Elizabeth H Hammond
    Intermountain Healthcare, University of Utah School of Medicine, Salt Lake City, UT, USA
    J Clin Oncol 28:2784-95. 2010
    ..To develop a guideline to improve the accuracy of immunohistochemical (IHC) estrogen receptor (ER) and progesterone receptor (PgR) testing in breast cancer and the utility of these receptors as predictive markers...
  88. pmc Estrogen receptor alpha controls a gene network in luminal-like breast cancer cells comprising multiple transcription factors and microRNAs
    Luigi Cicatiello
    Department of General Pathology, Second University of Naples, Napoli, Italy
    Am J Pathol 176:2113-30. 2010
    ....
  89. ncbi MicroRNA-21 targets the tumor suppressor gene tropomyosin 1 (TPM1)
    Shuomin Zhu
    Department of Medical Microbiology, Immunology, and Cell Biology, Southern Illinois University School of Medicine, Springfield, IL 62794, USA
    J Biol Chem 282:14328-36. 2007
    ..Thus, down-regulation of TPM1 by mir-21 may explain, at least in part, why suppression of mir-21 can inhibit tumor growth, further supporting the notion that mir-21 functions as an oncogene...
  90. ncbi Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer
    Anna V Ivshina
    Genome Institute of Singapore, Singapore
    Cancer Res 66:10292-301. 2006
    ....
  91. ncbi Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma
    Torsten O Nielsen
    Genetic Pathology Evaluation Centre, University of British Columbia, Vancouver Hospital and British Columbia Cancer Agency, Vancouver, British Columbia, Canada
    Clin Cancer Res 10:5367-74. 2004
    ..Currently, there exist clinical assays that identify ER+/luminal and HER2-overexpressing tumors, and we sought to develop a clinical assay for breast basal-like tumors...
  92. doi Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations
    Guido Sauter
    Department of Pathology and Norris Comprehensive Cancer Center, University of Southern California Keck School of Medicine, 1441 Eastlake Ave, Ste 5409, Los Angeles, CA 90033
    J Clin Oncol 27:1323-33. 2009
    ..Until other methods achieve similar test accuracy, reproducibility, and predictive value, we suggest FISH as the primary HER-2 testing modality for women with breast cancer who are candidates for HER-2-targeted therapies...
  93. pmc A microRNA signature of hypoxia
    Ritu Kulshreshtha
    Molecular Oncology Research Institute, Tufts New England Medical Center, Boston, Massachusetts 02111, USA
    Mol Cell Biol 27:1859-67. 2007
    ..Interestingly, the vast majority of hypoxia-induced microRNAs are also overexpressed in a variety of human tumors...
  94. doi Circulating microRNAs as novel minimally invasive biomarkers for breast cancer
    Helen M Heneghan
    Department of Surgery, National University of Ireland, Galway, Ireland
    Ann Surg 251:499-505. 2010
    ..The objective of this study was to investigate the potential of circulating microRNAs as novel breast cancer biomarkers...
  95. ncbi Breast cancer as a global health concern
    Steven S Coughlin
    Environmental Epidemiology Service, Office of Public Health and Environmental Hazards, Department of Veterans Affairs, Washington, DC, USA
    Cancer Epidemiol 33:315-8. 2009
    ..Additional data are needed for various geographic areas to assess resources required, cost-effectiveness, and humane approaches for preventing or controlling breast cancer in low resource settings in developing countries...
  96. doi Basal-like breast cancer: a critical review
    Emad A Rakha
    Department of Histopathology, Nottingham City Hospital National Health Service NHS Trust, UK
    J Clin Oncol 26:2568-81. 2008
    ..In this review, we discuss definition, heterogeneity, morphologic spectrum, relation to BRCA1, and clinical significance of this important class of breast cancer...
  97. ncbi BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells
    Gemma Molyneux
    The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, 237 Fulham Road, London SW3 6JB, UK
    Cell Stem Cell 7:403-17. 2010
    ..They also demonstrate that when target cells for transformation have the potential for phenotypic plasticity, tumor phenotypes may not directly reflect histogenesis. This has important implications for cancer prevention strategies...
  98. doi A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer
    Pierre Farmer
    Swiss National Centre of Competence in Research Molecular Oncology, Swiss Institute for Experimental Cancer Research, Ecole Polytechnique Federale de Lausanne, School of Life Sciences, Epalinges s Lausanne, Switzerland
    Nat Med 15:68-74. 2009
    ..These findings identify a previously undescribed resistance mechanism to FEC treatment and suggest that antistromal agents may offer new ways to overcome resistance to chemotherapy...
  99. ncbi Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
    D J Slamon
    Department of Medicine, U C L A School of Medicine 90024
    Science 244:707-12. 1989
    ..The data presented further support the concept that the HER-2/neu gene may be involved in the pathogenesis of some human cancers...
  100. pmc EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells
    Celina G Kleer
    Department of Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA
    Proc Natl Acad Sci U S A 100:11606-11. 2003
    ..This study provides compelling evidence for a functional link between dysregulated cellular memory, transcriptional repression, and neoplastic transformation...
  101. pmc HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression
    E Laughner
    Institute of Genetic Medicine, Departments of Pediatrics and Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287-3914, USA
    Mol Cell Biol 21:3995-4004. 2001
    ..These data provide a molecular basis for VEGF induction and tumor angiogenesis by heregulin-HER2 signaling and establish a novel mechanism for the regulation of HIF-1alpha expression...

Research Grants88

  1. Flaxseed vs. aromatase inhibitors: breast tumor characteristics and prognosis
    Susan McCann; Fiscal Year: 2007
    ....
  2. CELLULAR MECHANISMS IN THE INDUCTION OF AROMATASE
    CAROLE MENDELSON; Fiscal Year: 2009
    ..We believe that this research will provide important insight into tissue-specific regulation of aromatase in normal physiology and in pathophysiologic states. ..
  3. Dissecting the Mechanisms of Tamoxifen Action
    Manohar Ratnam; Fiscal Year: 2009
    ..We propose to further investigate this and other mechanisms of tamoxifen action and in the process, to identify lead compounds whose properties are superior to that of tamoxifen. ..
  4. A Resource for magnetic resonance and optical imaging
    Ravinder Reddy; Fiscal Year: 2010
    ..Developments in the TR&D are driven by four driving biomedical projects and six collaborative and service projects from both within and outside the primary institution. ..
  5. Effects of herbs on transcription and cell proliferation
    Dale Leitman; Fiscal Year: 2003
    ..This information can also provide a scientific basis to prioritize herbs for clinical trials evaluation for their ability to prevent and treat breast cancer. ..
  6. Effects of herbs on transcription and cell proliferation
    Dale Leitman; Fiscal Year: 2002
    ..This information can also provide a scientific basis to prioritize herbs for clinical trials evaluation for their ability to prevent and treat breast cancer. ..
  7. Fatty Acid Synthase:Molecular Target for Breast Cancer Therapy & Chemoprevention
    Ruth Lupu; Fiscal Year: 2009
    ....
  8. Fatty Acid Synthase:Molecular Target for Breast Cancer Therapy & Chemoprevention
    Ruth Lupu; Fiscal Year: 2007
    ....
  9. Molecular Epidemiology of Secondary Lung Cancer
    Peter Shields; Fiscal Year: 2007
    ..RESEARCH GRANT TABLE OF CONTENTS Page Numbers Face Page .................................................................................................................................................. 1 Description, ..
  10. Fatty Acid Synthase: Characterization as a Novel Molecular Target for Breast Can*
    Ruth Lupu; Fiscal Year: 2006
    ....
  11. Fatty Acid Synthase /Molecular Target /Breast Cancer The
    Ruth Lupu; Fiscal Year: 2005
    ....
  12. MODIFIERS OF CARCINOGENESIS--ENVIRONMENTAL PAH MIXTURES
    William Baird; Fiscal Year: 2005
    ..This will aid in the development of methods for predicting the relative carcinogenic potency based upon the PAH composition of complex environmental mixtures. ..
  13. MODIFIERS OF CARCINOGENESIS--ENVIRONMENTAL PAH MIXTURES
    William Baird; Fiscal Year: 2003
    ..This will aid in the development of methods for predicting the relative carcinogenic potency based upon the PAH composition of complex environmental mixtures. ..
  14. MODIFIERS OF CARCINOGENESIS--ENVIRONMENTAL PAH MIXTURES
    William Baird; Fiscal Year: 2004
    ..This will aid in the development of methods for predicting the relative carcinogenic potency based upon the PAH composition of complex environmental mixtures. ..
  15. MODIFIERS OF CARCINOGENESIS--ENVIRONMENTAL PAH MIXTURES
    William Baird; Fiscal Year: 2002
    ..This will aid in the development of methods for predicting the relative carcinogenic potency based upon the PAH composition of complex environmental mixtures. ..
  16. MODIFIERS OF CARCINOGENESIS--ENVIRONMENTAL PAH MIXTURES
    William Baird; Fiscal Year: 2001
    ..This will aid in the development of methods for predicting the relative carcinogenic potency based upon the PAH composition of complex environmental mixtures. ..
  17. RADIOPHARMACEUTICALS FOR BREAST TUMOR IMAGING & THERAPY
    John Katzenellenbogen; Fiscal Year: 2001
    ..These investigations should lead to substantial advances in the availability of diagnostic imaging gents for ER+ tumors and ER subtype- selective imaging agents, to the evaluation in vivo of radiotherapeutic ER ligands. ..
  18. RADIOPHARMACEUTICALS FOR BREAST TUMOR IMAGING & THERAPY
    John Katzenellenbogen; Fiscal Year: 2003
    ..These investigations should lead to substantial advances in the availability of diagnostic imaging gents for ER+ tumors and ER subtype- selective imaging agents, to the evaluation in vivo of radiotherapeutic ER ligands. ..
  19. RADIOPHARMACEUTICALS FOR BREAST TUMOR IMAGING & THERAPY
    John Katzenellenbogen; Fiscal Year: 1999
    ..These investigations should lead to substantial advances in the availability of diagnostic imaging gents for ER+ tumors and ER subtype- selective imaging agents, to the evaluation in vivo of radiotherapeutic ER ligands. ..
  20. RADIOPHARMACEUTICALS FOR BREAST TUMOR IMAGING & THERAPY
    John Katzenellenbogen; Fiscal Year: 2000
    ..These investigations should lead to substantial advances in the availability of diagnostic imaging gents for ER+ tumors and ER subtype- selective imaging agents, to the evaluation in vivo of radiotherapeutic ER ligands. ..
  21. RADIOPHARMACEUTICALS FOR BREAST TUMOR IMAGING & THERAPY
    John Katzenellenbogen; Fiscal Year: 2005
    ..These investigations should lead to substantial advances in the availability of diagnostic imaging gents for ER+ tumors and ER subtype- selective imaging agents, to the evaluation in vivo of radiotherapeutic ER ligands. ..
  22. RADIOPHARMACEUTICALS FOR BREAST TUMOR IMAGING & THERAPY
    John Katzenellenbogen; Fiscal Year: 2006
    ..These investigations should lead to substantial advances in the availability of diagnostic imaging gents for ER+ tumors and ER subtype- selective imaging agents, to the evaluation in vivo of radiotherapeutic ER ligands. ..
  23. Targeted tumoricidal bacteria
    Ming Zhao; Fiscal Year: 2010
    ..Exploitation of the tumor-killing capability of Salmonella has great potential for a new paradigm of cancer therapy. ..
  24. HETEROGENEITY OF ESTROGEN RECEPTOR STRUCTURE AND ACTION
    Beth Schachter; Fiscal Year: 1991
    ....
  25. RADIOPHARMACEUTICALS FOR BREAST TUMOR IMAGING & THERAPY
    John Katzenellenbogen; Fiscal Year: 2002
    ..These investigations should lead to substantial advances in the availability of diagnostic imaging gents for ER+ tumors and ER subtype- selective imaging agents, to the evaluation in vivo of radiotherapeutic ER ligands. ..
  26. RADIOPHARMACEUTICALS FOR BREAST TUMOR IMAGING & THERAPY
    John Katzenellenbogen; Fiscal Year: 2004
    ..These investigations should lead to substantial advances in the availability of diagnostic imaging gents for ER+ tumors and ER subtype- selective imaging agents, to the evaluation in vivo of radiotherapeutic ER ligands. ..
  27. Protein-DNA Drug Carriers for Tumor Targeting
    Lali Medina Kauwe; Fiscal Year: 2009
    ..As HER2+ breast cancer does not respond well to conventional therapies, this alternative therapy could provide a significant contribution to breast cancer treatment, and could be modified to target therapy to other types of cancer. ..
  28. Protein-DNA Drug Carriers for Tumor Targeting
    Lali K Medina Kauwe; Fiscal Year: 2010
    ..As HER2+ breast cancer does not respond well to conventional therapies, this alternative therapy could provide a significant contribution to breast cancer treatment, and could be modified to target therapy to other types of cancer. ..
  29. BREAST CANCER METASTASES TO BONE--ROLE OF PTHRP & TGFB
    Theresa Guise; Fiscal Year: 2000
    ..Combinations of bisphosphonates with factor-specific therapy will be studied for synergistic effects. ..
  30. BREAST CANCER METASTASES TO BONE--ROLE OF PTHRP & TGFB
    Theresa Guise; Fiscal Year: 1999
    ..Combinations of bisphosphonates with factor-specific therapy will be studied for synergistic effects. ..
  31. ORGANOCHLORINE COMPOUNDS AND RISK OF BREAST CANCER
    Tongzhang Zheng; Fiscal Year: 1993
    ..Statistical analyses will be performed using standard multivariable techniques to address the study hypotheses and to control for confounding...
  32. Flaxseed vs. aromatase inhibitors: breast tumor characteristics and prognosis
    Susan McCann; Fiscal Year: 2009
    ....
  33. Radiopharmaceuticals for Breast Tumor Imaging and Therapy
    John Katzenellenbogen; Fiscal Year: 2009
    ..These agents could improve the selection of patients for individualized and optimized hormone therapy, sparing them the morbidity associated with standard radiation and chemotherapy which would provide them with no further benefit. ..
  34. Radiopharmaceuticals for Breast Tumor Imaging and Therapy
    John Katzenellenbogen; Fiscal Year: 2007
    ..These agents could improve the selection of patients for individualized and optimized hormone therapy, sparing them the morbidity associated with standard radiation and chemotherapy which would provide them with no further benefit. ..
  35. Radiopharmaceuticals for Breast Tumor Imaging and Therapy
    John A Katzenellenbogen; Fiscal Year: 2010
    ..These agents could improve the selection of patients for individualized and optimized hormone therapy, sparing them the morbidity associated with standard radiation and chemotherapy which would provide them with no further benefit. ..
  36. CELLULAR MECHANISMS IN THE INDUCTION OF AROMATASE
    CAROLE MENDELSON; Fiscal Year: 2007
    ..We believe that this research will provide important insight into tissue-specific regulation of aromatase in normal physiology and in pathophysiologic states. ..
  37. CELLULAR MECHANISMS IN THE INDUCTION OF AROMATASE
    CAROLE MENDELSON; Fiscal Year: 2006
    ..We believe that this research will provide important insight into tissue-specific regulation of aromatase in normal physiology and in pathophysiologic states. ..
  38. CELLULAR MECHANISMS IN THE INDUCTION OF AROMATASE
    CAROLE MENDELSON; Fiscal Year: 2005
    ..We believe that this research will provide important insight into tissue-specific regulation of aromatase in normal physiology and in pathophysiologic states. ..
  39. Molecular Epidemiology of Smoking & Breast Cancer
    KATHLEEN CONWAY DORSEY; Fiscal Year: 2005
    ..If breast cancer can be attributed, in part, to cigarette smoking, then smoking prevention or cessation should reduce exposure and thus decrease the incidence of breast cancer. ..
  40. Molecular Epidemiology of Smoking & Breast Cancer
    Kathleen Conway Dorsey; Fiscal Year: 2004
    ..If breast cancer can be attributed, in part, to cigarette smoking, then smoking prevention or cessation should reduce exposure and thus decrease the incidence of breast cancer. ..
  41. Molecular Epidemiology of Smoking & Breast Cancer
    Kathleen Conway Dorsey; Fiscal Year: 2003
    ..If breast cancer can be attributed, in part, to cigarette smoking, then smoking prevention or cessation should reduce exposure and thus decrease the incidence of breast cancer. ..
  42. Interactions Between Dietary Soy Components & Tamoxifen
    Jin Rong Zhou; Fiscal Year: 2003
    ....
  43. Interactions Between Dietary Soy Components & Tamoxifen
    Jin Rong Zhou; Fiscal Year: 2002
    ....
  44. Dietary lignan effects on hormone, growth, and signaling factors in breast tumors
    Susan McCann; Fiscal Year: 2009
    ..The results of this study may provide us with important information that can be useful in understanding the effect of diet on development of different breast cancer sub-types. ..
  45. Immunoregulation and immunotherapy of breast cancer
    Robert Vonderheide; Fiscal Year: 2009
    ..The long-term goal is to develop an immune-based therapy that offers clinical benefit to patients with hormone receptor positive breast cancer. ..
  46. Coexpression of EGFRvlll/ErbB2 in Human Breast Cancer
    Careen Tang; Fiscal Year: 2001
    ..The results of the proposed studies may ultimately point to new directions of molecular therapies of breast cancer. ..
  47. Coexpression of EGFRvlll/ErbB2 in Human Breast Cancer
    Careen Tang; Fiscal Year: 2003
    ..The results of the proposed studies may ultimately point to new directions of molecular therapies of breast cancer. ..
  48. Coexpression of EGFRvlll/ErbB2 in Human Breast Cancer
    Careen Tang; Fiscal Year: 2005
    ..The results of the proposed studies may ultimately point to new directions of molecular therapies of breast cancer. ..
  49. Coexpression of EGFRvlll/ErbB2 in Human Breast Cancer
    Careen Tang; Fiscal Year: 2004
    ..The results of the proposed studies may ultimately point to new directions of molecular therapies of breast cancer. ..
  50. Immunoregulation and immunotherapy of breast cancer
    Robert H Vonderheide; Fiscal Year: 2010
    ..The long-term goal is to develop an immune-based therapy that offers clinical benefit to patients with hormone receptor positive breast cancer. ..
  51. Coexpression of EGFRvlll/ErbB2 in Human Breast Cancer
    Careen Tang; Fiscal Year: 2002
    ..The results of the proposed studies may ultimately point to new directions of molecular therapies of breast cancer. ..
  52. Int5/Aromatase Effect of Breast Estrogen in Neoplasia
    RAJESHWAR TEKMAL; Fiscal Year: 2003
    ..abstract_text> ..
  53. Int5/Aromatase Effect of Breast Estrogen in Neoplasia
    RAJESHWAR TEKMAL; Fiscal Year: 2002
    ..abstract_text> ..
  54. Int5/Aromatase Effect of Breast Estrogen in Neoplasia
    RAJESHWAR TEKMAL; Fiscal Year: 2001
    ..abstract_text> ..
  55. Int5/Aromatase Effect of Breast Estrogen in Neoplasia
    RAJESHWAR TEKMAL; Fiscal Year: 2005
    ..abstract_text> ..
  56. HER2 LIGAND IN HUMAN BREAST TUMORS
    KERMIT CARRAWAY; Fiscal Year: 1999
    ....
  57. HER2 LIGAND IN HUMAN BREAST TUMORS
    KERMIT CARRAWAY; Fiscal Year: 2001
    ....
  58. HER2 LIGAND IN HUMAN BREAST TUMORS
    KERMIT CARRAWAY; Fiscal Year: 2001
    ....
  59. HER2 LIGAND IN HUMAN BREAST TUMORS
    KERMIT CARRAWAY; Fiscal Year: 2000
    ....
  60. ROLE AND FUNCTIONS OF PYRIMIDINES IN CANCER THERAPY
    Giuseppe Pizzorno; Fiscal Year: 2000
    ..Specific alterations of UPase genetic information will be achieved by: a) targeted disruption of UPase gene to nullify the UPase allele, and conversely, b) UPase gene transfer to elevate the UPase expression and activity in tissues. ..
  61. ROLE AND FUNCTIONS OF PYRIMIDINES IN CANCER THERAPY
    Giuseppe Pizzorno; Fiscal Year: 2001
    ..Specific alterations of UPase genetic information will be achieved by: a) targeted disruption of UPase gene to nullify the UPase allele, and conversely, b) UPase gene transfer to elevate the UPase expression and activity in tissues. ..
  62. ROLE AND FUNCTIONS OF PYRIMIDINES IN CANCER THERAPY
    Giuseppe Pizzorno; Fiscal Year: 2003
    ..Specific alterations of UPase genetic information will be achieved by: a) targeted disruption of UPase gene to nullify the UPase allele, and conversely, b) UPase gene transfer to elevate the UPase expression and activity in tissues. ..
  63. ROLE AND FUNCTIONS OF PYRIMIDINES IN CANCER THERAPY
    Giuseppe Pizzorno; Fiscal Year: 2002
    ..Specific alterations of UPase genetic information will be achieved by: a) targeted disruption of UPase gene to nullify the UPase allele, and conversely, b) UPase gene transfer to elevate the UPase expression and activity in tissues. ..
  64. ROLE AND FUNCTIONS OF PYRIMIDINES IN CANCER THERAPY
    Giuseppe Pizzorno; Fiscal Year: 2004
    ..Specific alterations of UPase genetic information will be achieved by: a) targeted disruption of UPase gene to nullify the UPase allele, and conversely, b) UPase gene transfer to elevate the UPase expression and activity in tissues. ..
  65. Mechanisms of Src activation and its role in latent bone metastasis of breast and
    Xiang H F Zhang; Fiscal Year: 2010
    ..Because of the availability of FDA-approved Src inhibitors, this study will carry significant clinical implications and may suggest novel therapeutic strategies that can be immediately subject to clinical trials. ..
  66. Role of Stat3 in Breast Cancer Tumorigenesis
    Jacqueline Bromberg; Fiscal Year: 2009
    ....
  67. Role of Stat3 in Breast Cancer Tumorigenesis
    Jacqueline F Bromberg; Fiscal Year: 2010
    ....
  68. MicroRNA Signature of Tamoxifen Resistance in Breast Cancer
    Sarmila Majumder; Fiscal Year: 2010
    ..This study will also help us design future clinical trials based on these molecular predictions. ..
  69. MicroRNA Signature of Tamoxifen Resistance in Breast Cancer
    Sarmila Majumder; Fiscal Year: 2009
    ..This study will also help us design future clinical trials based on these molecular predictions. ..
  70. Targeted Gold Nanoparticle-Bioconjugates for Imaging Breast Cancer
    Raghuraman Kannan; Fiscal Year: 2009
    ..This has the potential to improve the early detection and diagnosis of breast cancer. ..
  71. Breast CT scanner for earlier cancer detection
    John Boone; Fiscal Year: 2004
    ..that particularly warrant screening using breast CT. The Phase II trial will shed more light on this issue. ..
  72. Breast CT scanner for earlier cancer detection
    John Boone; Fiscal Year: 2005
    ..that particularly warrant screening using breast CT. The Phase II trial will shed more light on this issue. ..
  73. Mechanisms of Action and Signaling by Steroid Hormone Antagonists
    Douglas V Faller; Fiscal Year: 2010
    ....
  74. Breast CT scanner for earlier cancer detection
    John Boone; Fiscal Year: 2002
    ..that particularly warrant screening using breast CT. The Phase II trial will shed more light on this issue. ..
  75. Breast CT scanner for earlier cancer detection
    John Boone; Fiscal Year: 2003
    ..that particularly warrant screening using breast CT. The Phase II trial will shed more light on this issue. ..
  76. Mechanisms of Action and Signaling by Steroid Hormone Antagonists
    DOUGLAS FALLER; Fiscal Year: 2009
    ....
  77. Breast CT scanner for earlier cancer detection
    John Boone; Fiscal Year: 2006
    ..that particularly warrant screening using breast CT. The Phase II trial will shed more light on this issue. ..
  78. Targeted Gold Nanoparticle-Bioconjugates for Imaging Breast Cancer
    Raghuraman Kannan; Fiscal Year: 2007
    ..This has the potential to improve the early detection and diagnosis of breast cancer. ..
  79. Dissecting the Mechanisms of Tamoxifen Action
    Manohar Ratnam; Fiscal Year: 2012
    ..We propose to further investigate this and other mechanisms of tamoxifen action and in the process, to identify lead compounds whose properties are superior to that of tamoxifen. ..
  80. Endocrine resistance in breast cancer
    ROBERT R CLARKE; Fiscal Year: 2011
    ....
  81. Aptamer-siRNA Chimeras Targeting HER2-Positive Breast Cancers
    PALOMA HOBAN GIANGRANDE; Fiscal Year: 2010
    ..In addition, this work will refine general methods for establishing a platform technology that can be applied towards developing novel treatments for several human pathological conditions that would benefit from targeted gene silencing. ..
  82. Endocrine resistance in breast cancer
    Robert Clarke; Fiscal Year: 2009
    ....
  83. Dissecting the Mechanisms of Tamoxifen Action
    Manohar Ratnam; Fiscal Year: 2010
    ..We propose to further investigate this and other mechanisms of tamoxifen action and in the process, to identify lead compounds whose properties are superior to that of tamoxifen. ..
  84. Aptamer-siRNA Chimeras Targeting HER2-Positive Breast Cancers
    PALOMA GIANGRANDE; Fiscal Year: 2009
    ..In addition, this work will refine general methods for establishing a platform technology that can be applied towards developing novel treatments for several human pathological conditions that would benefit from targeted gene silencing. ..
  85. Endocrine resistance in breast cancer
    ROBERT R CLARKE; Fiscal Year: 2010
    ....
  86. Interactions Between Dietary Soy Components & Tamoxifen
    Jin Rong Zhou; Fiscal Year: 2001
    ....